Neurocrine Biosciences Inc (NBIX) Reports Strong Growth in INGREZZA Sales for Q4 and Full Year 2023

INGREZZA Net Product Sales Surge as Company Prepares for New Drug Applications

Related Keywords

Kevin Gorman ,Neurocrine Biosciences ,Neurocrine Bioscience ,Analysis Of Company Performance ,Neurocrine Biosciences Inc ,Income Statement ,Balance Sheet ,Devin Gorman ,Product Sales ,Cash Equivalents ,Ingrezza ,Aap ,Pharmaceutical Company ,Revenue Growth ,Financial Results ,Net Income ,